May 31, 2011

Sanofi GetGoal Program on Lyxumia®, as an Add-on to Basal Insulin, Shows Significant Positive Phase III Results

- Reduction in HbA1c without Significant Increase in Hypoglycemia -

 

Sanofi GetGoal Program on Lyxumia®, as an Add-on to Basal Insulin, Shows Significant Positive Phase III Results
- Reduction in HbA1c without Significant Increase in Hypoglycemia -

Paris, France – May 31, 2011 – Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that new results from a Phase III study showed that the investigational product Lyxumia® (lixisenatide), when used as an add-on therapy to basal insulin (in association with or without metformin), achieved its primary efficacy endpoint of significantly reducing HbA1c versus placebo for patients with type 2 diabetes without significantly increasing their risk of hypoglycemia.